key: cord-0853342-5577lg5q authors: Abusrewil, Zakarya; Alhudiri, Inas M.; Kaal, Hamza H.; El Meshri, Salah Eldin; Ebrahim, Fawzi O.; Dalyoum, Tarek; Efrefer, Abdussamee A.; Ibrahim, Khaled; Elfghi, Mohammed B.; Abusrewil, Suleiman; Elzagheid, Adam title: Time scale performance of rapid antigen testing for SARS‐CoV‐2: Evaluation of 10 rapid antigen assays date: 2021-07-28 journal: J Med Virol DOI: 10.1002/jmv.27186 sha: 34c4bd75a03fc75907a84473a9b95cd585d3e00d doc_id: 853342 cord_uid: 5577lg5q There is a great demand for more rapid tests for SARS‐CoV‐2 detection to reduce waiting time, boost public health strategies for combating disease, decrease costs, and prevent overwhelming laboratory capacities. This study was conducted to assess the performance of 10 lateral flow device viral antigen immunoassays for the detection of SARS‐CoV‐2 in nasopharyngeal swab specimens. We analyzed 231 nasopharyngeal samples collected from October 2020 to December 2020, from suspected COVID‐19 cases and contacts of positive cases at Biotechnology Research Center laboratories, Tripoli, Libya. The performance of 10 COVID‐19 Antigen (Ag) rapid test devices for the detection of SARS‐CoV‐2 antigen was compared to a quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR). In this study, 161 cases had symptoms consistent with COVID‐19. The mean duration from symptom onset was 6.6 ± 4.3 days. The median cycle threshold (C (t)) of positive samples was 25. Among the 108 positive samples detected by RT‐qPCR, the COVID‐19 antigen (Ag) tests detected 83 cases correctly. All rapid Ag test devices used in this study showed 100% specificity. While tests from six manufacturers had an overall sensitivity range from 75% to 100%, the remaining four tests had a sensitivity of 50%–71.43%. Sensitivity during the first 6 days of symptoms and in samples with high viral loads (C (t) < 25), was 100% in all but two of the test platforms. False‐negative samples had a median C (t) of 34 and an average duration of onset of symptoms of 11.3 days (range = 5–20 days). Antigen test diagnosis has high sensitivity and specificity in early disease when patients present less than 7 days of symptom onset. Patients are encouraged to test as soon as they get COVID‐19‐related symptoms within 1 week and to seek medical advice within 24 h if they develop disturbed smell/taste. The use of rapid antigen tests is important for controlling the COVID‐19 pandemic and reducing the burden on molecular diagnostic laboratories. Nucleic acid amplification test using quantitative reverse transcriptionpolymerase chain reaction (RT-qPCR) assay is currently the mainstay diagnostic test for COVID-19 in most laboratories. However, results of RT-qPCR assays can take several days to deliver, hampering the disease containment efforts. Consequently, there is an emerging demand for more rapid and easier tests to reduce waiting time, boost public health strategies for combating disease, decrease costs, and prevent overwhelming laboratory capacities. SARS-CoV-2-rapid antigen tests have been largely developed and many countries have adopted them for diagnosis in triage and hospital settings and at points of entry. 1 However, many of these tests have not been independently validated. The World Health Organization (WHO) encourages laboratories to evaluate the performance of commercial rapid antigen assays to update the current evidence and recommend specific test kits. 2 According to previous studies, rapid antigen tests could be used in high-risk populations to quickly identify patients with infection and prevent disease transmission by repeat testing. 3 Evaluation of these tests showed also diagnostic performance in screening mass population. 4 Libyan health authorities have approved the use of rapid antigen tests in triage, isolation centers, and hospitals. 5 This study was conducted to assess the performance of 10 antigen-based rapid assays for the detection of SARS-CoV-2 in nasopharyngeal swab specimens from suspected COVID-19 cases and contacts. This was a prospective single-center study. A total of 231 patients with clinical features suggestive of COVID-19 or a history of close contact with COVID-19 positive patients were enrolled in this study from October 10 to December 31, 2020. However, there were financial difficulties to obtain adequate quantities of the antigen test device to study a larger sample size for each type during the pandemic, and hence the number of samples tested was between 15 and 39 depending on the kit contents. The majority of patients were having symptoms suggestive of COVID-19 (70%). A quarter of participants were asymptomatic and were in contact with the COVID-19 positive case. Few patients were asymptomatic but had no history of contact. Duration since symptom onset was variable among the cases with an average of 7 days (Table 1 ). We evaluated the performance of 10 rapid antigen tests for SARS-CoV-2. We had also analyzed 31 samples out of the total number of 231 to evaluate the reliability of reusing swabs after rapid Ag testing for RT-qPCR. There is an additional step in rapid Ag testing in which swabs are placed in lysis buffer before being transported into VTM. Results were compared to those obtained from swabs used directly for the standard RT-qPCR procedure. Sensitivity, specificity, positive, and negative predictive values and accuracy were calculated using MedCalc online statistical software. 6 Laboratory COVID-19 prevalence data were obtained from the Biotechnology Research Center case registry for the study period Positive predictive value: Negative predictive value: Accuracy: Sensitivity × prevalence + specificity × (1 − Prevalence). We evaluated the sensitivity of each antigen test from the first day of symptoms up to 6, >7, 7-9, 10-12, and >12 days (Figure 1 ). Sensitivity during the first 6 days of symptoms and in samples with high viral loads (C t < 25), was 100% in all but two (Assut and AMP) of the test platforms ( Table 3 ). The median RT-qPCR cycle threshold value of positive samples was 25. The majority of antigen test platforms had excellent performance during the first 6 days of symptoms with sensitivity ranging between 75% and 100% (Table 3) . It is worth mentioning that three participants (3/58, 5.2%) who were asymptomatic at the time of testing with a history of close contact with a confirmed SARS-CoV-2 case tested positive by antigen test (Espline & Rapigen rapid Ag tests). The C t s of their RT-qPCR assay were 23, 24, and 25, and the duration since contact was 5, 6, and 10 days, respectively. All other asymptomatic cases with exposure were correctly diagnosed as negative. All asymptomatic cases with no history of exposure were also tested negative by the Ag test. Among symptomatic patients, the sensitivity was 77%. Patients who experienced a change in smell/taste were 41. More Rapid antigen testing is cost-effective, easy to use, and can be manufactured in large quantities. The timeliness of the results they provided will reduce the load on the diagnostic laboratories. visible to the reader. Therefore, an additional independent reader is recommended when low viral loads are expected to reduce subjectivity and confirm the diagnosis but for most cases, one reader is sufficient for interpreting the results. We also do not recommend placing the same nasopharyngeal swab used for antigen test in VTM for RT-qPCR analysis as the viral material will be diluted and may give false-negative results. Since SARS-CoV-2 cases have been increasing with the emergence of new variants, 11 and numerous antigen tests were manufactured, it is important to evaluate them before implementation. Although there is more risk of developing false-negative results after 7 days of symptom onset, this is largely counterbalanced by the rapidity of the test especially when used in the targeted population. Our study shows that all COVID-19 Ag tests had good specificity for SARS-CoV-2 detection in nasopharyngeal swab samples but had a good sensitivity only for cases within 7 days of developing symptoms (higher viral loads). We proposed a strategy for use of rapid antigen tests in symptomatic patients according to our results and experience as shown in the flowcharts (Figure 2A,B) . Although the procedure is relatively easy to perform, testing with Ag rapid tests should be conducted by It is important to note that the use of rapid antigen tests requires careful respiratory sample management, waste disposal, and biosafety considerations. The incubation period of SARS-CoV-2 infection was estimated between 3 and 6 days with a median incubation of 4 days. 12 This study has some limitations. First, the sample size was small for each individual antigen rapid test kit. Second, because the data was collected prospectively based on the presence of symptoms or history of contact with an infected patient, it was difficult to select patients with different C t values in enough size. However, if we assumed that the performance of all antigen rapid test devices was similar, the data would be reliable enough to give credible results. Rapid Ag testing performance is mostly affected by symptoms duration, viral load, manufacturing company, operator experience, and qualification. In addition, new SARS-COV-2 variants may alter the performance especially with spike proteins targeted rapid ag tests. 20, 21 In conclusion, rapid Ag tests have high sensitivity and specificity in early disease when patients present before 7 days of symptom onset. Patients are encouraged to test as soon as they get COVID-19-related symptoms within 1 week and to seek medical advice within 24 h if they develop disturbed smell/taste. The use of rapid antigen tests is important for controlling the COVID-19 pandemic and reducing the burden on molecular diagnostic laboratories. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance A) Flowchart of the proposed use of rapid antigen tests in suspected COVID-19 cases with symptoms duration less than 7 days B) Flowchart of the proposed use of rapid antigen tests in suspected COVID-19 cases with symptoms duration of more than 7 days detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immu noassays Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms COVID-19: rapid antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation of sensitivity and specificity for mass-testing Press conference for scientific consultancy committee for coronavirus epidemic in Libya MedCalc's Diagnostic test evaluation calculator Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms Evaluation of clinical utility of novel coronavirus antigen detection reagent Genetic variants of SARS-CoV-2-what do they mean? Clinical characteristics of coronavirus disease 2019 in China Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Magnetic resonance imaging of COVID-19 anosmic patients reveals abnormalities of the olfactory bulb: preliminary prospective study Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia cohort study Predicting infectious SARS-CoV-2 from diagnostic samples Virological assessment of hospitalized patients with COVID-2019 Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards Covid-19: innova lateral flow test is not fit for "test and release" strategy, say experts The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity Time scale performance of rapid antigen testing for SARS-CoV-2: Evaluation of 10 rapid antigen assays The authors gratefully acknowledge the support of the Libyan authority for research, science, and technology and all lab researchers at the Biotechnology Research Center COVID-19 detection team. The authors declare that there are no conflict of interests. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Biotechnology Research Center Bioethics Committee. Informed consent was obtained from all individual participants included in the study. The corresponding authors had full access to all the data in the study and have final responsibility for the decision to submit for publica- Inas M. Alhudiri https://orcid.org/0000-0002-3371-0215Adam Elzagheid https://orcid.org/0000-0002-7086-5937